Core Viewpoint - Furuya Medical Technology (01696) has successfully passed the quality standard inspection for its long-acting botulinum toxin product DAXXIFY, marking a significant milestone for its market entry in China [1] Group 1: Product Development - DAXXIFY has met the stringent quality, safety, and efficacy standards set by the National Medical Products Administration of China, completing the final critical step before market launch [1] - The product is expected to enhance the diversity of the company's injectable filler offerings, providing consumers with more high-quality choices [1] Group 2: Business Impact - DAXXIFY is positioned as a strategic cornerstone for the company's injectable filler business, anticipated to serve as a second growth engine and generate sustainable consumable revenue [1] - The successful launch of DAXXIFY is expected to solidify the company's leading position in the global beauty and health industry [1]
复锐医疗科技高开逾4% 长效A型肉毒毒素产品达希斐通过中检院质量标准检验